Coherus Oncology Reports Q1 Results, LOQTORZI Revenue Growth, and Pipeline Progress; Finalizes $53.6M Offering

summarizeSummary

Coherus Oncology reported Q1 2026 financial results, showing year-over-year LOQTORZI revenue growth and significant pipeline progress, while also finalizing a $53.6 million public offering.

check_boxKey Events

• Q1 2026 Financial Results

  Net revenue from continuing operations was $12.3 million, with LOQTORZI net revenue reaching $11.8 million, a 61% increase over Q1 2025. Net loss from continuing operations improved to $36.9 million, or $(0.27) per share, compared to $(0.41) per share in Q1 2025.

• LOQTORZI Commercial Performance

  The company achieved its highest volume of new patient starts to date for LOQTORZI, despite a 5% sequential decrease in revenue from Q4 2025, attributed to severe weather and seasonality.

• Pipeline Advancement

  Enrollment is complete for the Phase 2 trial of casdozokitug in 1L uHCC, with initial data expected mid-2026. Multiple Phase 1b studies for tagmokitug are underway, with data readouts anticipated in mid-2026 and 2H 2026.

• Public Offering Finalized

  During Q1 2026, Coherus sold 32.89 million shares in a public offering, including the full exercise of the underwriters' over-allotment option, generating net proceeds of $53.6 million. This updates the previously reported proceeds of $47.0 million.

auto_awesomeAnalysis

This 8-K provides a comprehensive update on Coherus Oncology's first-quarter performance, highlighting progress in its strategic pivot to oncology. The company reported increased LOQTORZI revenue year-over-year and significant advancements in its pipeline, with key clinical trial milestones approaching. The filing also finalizes the details of a substantial public offering completed in Q1, which provided crucial capital to support ongoing operations and development. While the company continues to operate at a loss, the execution on its oncology strategy and pipeline progress are important for its long-term outlook.